Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Stephen Mason

Stephen Mason

Dr. Mason has been involved in drug discovery research for the past 19 years. He recently joined CaroGen Corp. as Executive Director, Discovery, to help advance a platform technology of Virus-like Vesicle (VLV) to develop therapeutic vaccines for HBV, oncology, and other indications. Since 2016, he has been a consultant in various capacities for small biotechs and potential start-up companies. From 2010 to 2015, he was Director, Discovery Virology at Bristol-Myers Squibb, leading research efforts toward remission/eradication of HIV-1 and HBV. Much of the focus of this work was on immune-modulatory mechanisms including PD-1/PD-L1. Under his guidance, anti-PD-L1 antibodies were tested in advanced animal disease models for both HIV-1 and HBV as well as in human clinical trials for HIV-1.

From 1998-2010, Dr. Mason was at Boehringer-Ingelheim (Canada) Ltd., where he led several drug discovery teams to find new antiretrovirals against HIV-1 targets including capsid and gag, integrase, reverse transcriptase, entry, vif and others. He also initiated research efforts toward HIV-1 remission/eradication at BI prior to moving to BMS. Early in his tenure at BI, he was involved in the discovery of novel inhibitors against Respiratory Syncytial Virus (RSV) RNA-dependent RNA polymerase and HIV-1 integrase. Prior to working in the pharmaceutical industry, Dr. Mason received his Ph.D. from the University of Toronto working on transcriptional antitermination. His post-doctoral studies were performed at University of Toronto and in Heidelberg, Germany, at the German Cancer Research Center (DKFZ) working on various aspects of transcriptional regulation of host RNA polymerase I and II. He is an inventor on 3 patents or patent applications and co-author of more than 30 peer reviewed publications.